AU2005216878B2 - Oxydecahydronaphthalene modulators of HM74 - Google Patents

Oxydecahydronaphthalene modulators of HM74 Download PDF

Info

Publication number
AU2005216878B2
AU2005216878B2 AU2005216878A AU2005216878A AU2005216878B2 AU 2005216878 B2 AU2005216878 B2 AU 2005216878B2 AU 2005216878 A AU2005216878 A AU 2005216878A AU 2005216878 A AU2005216878 A AU 2005216878A AU 2005216878 B2 AU2005216878 B2 AU 2005216878B2
Authority
AU
Australia
Prior art keywords
contain
combinations
substituted
heteroatom
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005216878A
Other languages
English (en)
Other versions
AU2005216878A1 (en
Inventor
Michael Angelastro
Haifeng Eishingdrelo
Stephan Henke
Theresa Kuntzweiler
Anne Minnich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of AU2005216878A1 publication Critical patent/AU2005216878A1/en
Application granted granted Critical
Publication of AU2005216878B2 publication Critical patent/AU2005216878B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
AU2005216878A 2004-02-20 2005-02-10 Oxydecahydronaphthalene modulators of HM74 Ceased AU2005216878B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54601204P 2004-02-20 2004-02-20
US60/546,012 2004-02-20
PCT/US2005/004095 WO2005082352A1 (en) 2004-02-20 2005-02-10 Oxydecahydronaphthalene modulators of hm74

Publications (2)

Publication Number Publication Date
AU2005216878A1 AU2005216878A1 (en) 2005-09-09
AU2005216878B2 true AU2005216878B2 (en) 2010-06-17

Family

ID=34910747

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005216878A Ceased AU2005216878B2 (en) 2004-02-20 2005-02-10 Oxydecahydronaphthalene modulators of HM74

Country Status (21)

Country Link
US (2) US7264937B2 (https=)
EP (1) EP1718293A1 (https=)
JP (1) JP2007526917A (https=)
KR (1) KR101145693B1 (https=)
CN (1) CN1929833A (https=)
AR (1) AR047708A1 (https=)
AU (1) AU2005216878B2 (https=)
BR (1) BRPI0507916A (https=)
CA (1) CA2556757C (https=)
CR (1) CR8537A (https=)
EC (1) ECSP066776A (https=)
IL (1) IL177106A (https=)
MA (1) MA28368A1 (https=)
ME (2) MEP17008A (https=)
NO (1) NO20064214L (https=)
RS (1) RS20060472A (https=)
RU (1) RU2006133539A (https=)
TN (1) TNSN06235A1 (https=)
TW (1) TWI354552B (https=)
WO (1) WO2005082352A1 (https=)
ZA (1) ZA200606687B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) * 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
AR059021A1 (es) * 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US8623873B2 (en) * 2007-06-28 2014-01-07 Intervet Inc. Substituted piperazines as CB1 antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048691A1 (de) * 1996-06-18 1997-12-24 Hoechst Aktiengesellschaft Ringannelierte dihydropyrane, verfahren zur herstellung sowie deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1007563A4 (en) * 1997-06-12 2003-04-16 Smithkline Beecham Corp HM74A RECEPTOR
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048691A1 (de) * 1996-06-18 1997-12-24 Hoechst Aktiengesellschaft Ringannelierte dihydropyrane, verfahren zur herstellung sowie deren verwendung

Also Published As

Publication number Publication date
RS20060472A (sr) 2008-11-28
MEP17008A (hr) 2010-06-10
IL177106A (en) 2012-03-29
RU2006133539A (ru) 2008-03-27
AR047708A1 (es) 2006-02-08
AU2005216878A1 (en) 2005-09-09
CR8537A (es) 2007-03-05
CN1929833A (zh) 2007-03-14
CA2556757C (en) 2011-05-03
TWI354552B (en) 2011-12-21
NO20064214L (no) 2006-09-18
ECSP066776A (es) 2006-11-16
US20080045586A1 (en) 2008-02-21
WO2005082352A1 (en) 2005-09-09
US7264937B2 (en) 2007-09-04
CA2556757A1 (en) 2005-09-09
ME00059B (me) 2010-06-10
JP2007526917A (ja) 2007-09-20
EP1718293A1 (en) 2006-11-08
IL177106A0 (en) 2006-12-10
TW200539864A (en) 2005-12-16
ZA200606687B (en) 2008-02-27
US20050187263A1 (en) 2005-08-25
KR20060127982A (ko) 2006-12-13
KR101145693B1 (ko) 2012-05-25
BRPI0507916A (pt) 2007-07-10
TNSN06235A1 (en) 2007-12-03
MA28368A1 (fr) 2006-12-01

Similar Documents

Publication Publication Date Title
US7556931B2 (en) Furosemide modulators of HM74
CN112057443B (zh) 苯磺酰胺类化合物的医药用途及其药物组合物
JP2006502169A (ja) Ｌｘｒ核内受容体結合性化合物
EP2567698B1 (en) GPR 17 agonists and screening assay
US20080045586A1 (en) Oxydecahydronaphthalene modulators of hm74
Bamborough et al. Progress towards the development of anti-inflammatory inhibitors of IKKβ
US20080069773A1 (en) Novel Sodium Channel
US8057990B2 (en) Screening method
MXPA06009413A (en) Oxydecahydronaphthalene modulators of hm74
US20090124002A1 (en) Alpha-1d calcium channel expressed in atrium
HK1098681A (en) Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation
JPWO2000014266A1 (ja) リガンド結合活性を示す組換えヒトｓｍ−１１０４４結合性レセプタータンパク質、およびその用途
JP2007228808A (ja) 自己免疫疾患の予防及び／又は治療剤の有効成分の同定方法
JPWO2000039315A1 (ja) Ｕｃｐ−２プロモーターおよびその用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired